Massachusetts College of Liberal Arts

Reaching new heights: Women in aviation soaring high at Auburn University

Retrieved on: 
Tuesday, November 16, 2021
List of Infinite Ryvius characters, Whirly-Girls, Women in Aviation International, Female, Student, Air Race Classic, Industry, Science, Atmosphere of Earth, Health, Engineering, Organization, Department, McDonnell Douglas F-15 Eagle, Auburn University, Aircraft, Oregon Department of Aviation, Community engagement, Carnegie, Multimedia, Research, White, Program, Auburn University Regional Airport, Partnership, Orange, Secret Warriors (Team White), Faculty, Air racing, Massachusetts College of Liberal Arts, Liberal arts education, College, Interdisciplinarity, Jet fuel, Airline, Satellite navigation device, Medicine

Since 2017, Auburn Aviation has competed annually in the Air Race Classic a traditionally transcontinental air race for female pilots.

Key Points: 
  • Since 2017, Auburn Aviation has competed annually in the Air Race Classic a traditionally transcontinental air race for female pilots.
  • This was the first year that Auburn Aviation had three teams competing, thanks to funds raised by Tiger Giving Day donors.
  • Birdsong said that women seeing women taking active roles in aviation leads to more women in aviation.
  • Given the success of Auburn Aviation over the years, one can expect the future of Auburn aviators to be bright.

Verseau Therapeutics Appoints Karen Tubridy as Chief Development Officer

Retrieved on: 
Tuesday, September 7, 2021
Biotechnology, Pharmaceutical, Health

Verseau Therapeutics, Inc. today announced the appointment of Karen Tubridy, Pharm.D.

Key Points: 
  • Verseau Therapeutics, Inc. today announced the appointment of Karen Tubridy, Pharm.D.
  • View the full release here: https://www.businesswire.com/news/home/20210907005167/en/
    Karen Tubridy, Pharm.D., Chief Development Officer of Verseau Therapeutics (Photo: Business Wire)
    Karen has decades of experience advancing therapeutic programs into the clinic and through to commercialization, said John Edwards, Chief Executive Officer of Verseau Therapeutics.
  • Karen previously served as Senior Vice President, Global Programs and Chief Development Officer at Akebia Therapeutics, where she was responsible for driving program strategy with operational responsibilities for its lead clinical asset through NDA and J-NDA.
  • Prior to joining Akebia, Karen was Chief Development Officer at Eleven Biotherapeutics, where she led clinical, regulatory, quality, program management and development strategy.